Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Melanoma 1Leukemia, Hairy Cell 1Histiocytosis 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 8Nivolumab 3Drug Therapy 3budigalimab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Gemcitabine 2Cisplatin 2venetoclax 1ulixertinib 1tislelizumab 1spartalizumab 1rovalpituzumab tesirine 1niraparib 1milademetan 1entrectinib 1durvalumab 1cobimetinib 1cemiplimab 1atezolizumab 1alectinib 1Specimen Handling 1Ramucirumab 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1PLX8394 1Molecular Diagnostic Techniques 1Leucovorin 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × PLX8394 × Dermatologic × Clear all
NCT02012231 2020-10-19

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Fore Biotherapeutics

Phase 1 Terminated
5 enrolled
DermatologicEndocrineGastrointestinalHead & NeckMyeloidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Hairy Cell, Melanoma, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis, Cholangiocarcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡